Overview

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Status:
Recruiting
Trial end date:
2025-01-30
Target enrollment:
Participant gender:
Summary
This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (OAG) or ocular hypertension (OHT) who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy.
Phase:
Phase 3
Details
Lead Sponsor:
Allergan
Treatments:
Bimatoprost